Sanofi: set to market MenQuadfi from 2021

(CercleFinance.com) - The CHMP recommends approval of Sanofi's MenQuadfi for immunisation against meningococcal invasive infections from 12 months of age.


The opinion is based on a broad international clinical program that has demonstrated a favourable safety profile and a high immune response against the four seropgroups (A, C, W and Y). Meningococco infections can cause death within 24 hours and result in severe permanent disabilities amongst survivors.

A final decision following this favourable opinion of the CHMP is expected to be taken by the end of the year. MenQuadfi should then be gradually marketed in Europe from 2021.

It is being evaluated by various health authorities for local use to contribute to preventive efforts.


Copyright (c) 2020 CercleFinance.com. All rights reserved.